» Articles » PMID: 38469405

Intestinal Mucosal Barrier: a Potential Target for Traditional Chinese Medicine in the Treatment of Cardiovascular Diseases

Overview
Journal Front Pharmacol
Date 2024 Mar 12
PMID 38469405
Authors
Affiliations
Soon will be listed here.
Abstract

Cardiovascular disease (CVD) is a serious public health problem, and among non-communicable diseases, CVD is now the leading cause of mortality and morbidity worldwide. CVD involves multiple organs throughout the body, especially the intestinal tract is the first to be involved. The impairment of the intestinal mucosal barrier is considered a significant pathological alteration in CVD and also contributes to the accelerated progression of the disease, thereby offering novel insights for CVD prevention and treatment. The treatment of Chinese medicine is characterized by multi-metabolites, multi-pathways, and multi-targets. In recent years, the studies of Traditional Chinese Medicine (TCM) in treating CVD by repairing the intestinal mucosal barrier have gradually increased, showing great therapeutic potential. This review summarizes the studies related to the treatment of CVD by TCM (metabolites of Chinese botanical drugs, TCM formulas, and Chinese patent medicine) targeting the repair of the intestinal mucosal barrier, as well as the potential mechanisms. We have observed that TCM exerts regulatory effects on the structure and metabolites of gut microbiota, enhances intestinal tight junctions, improves intestinal dyskinesia, repairs intestinal tissue morphology, and preserves the integrity of the intestinal vascular barrier through its anti-inflammatory, antioxidant, and anti-apoptotic properties. These multifaceted attributes position TCM as a pivotal modulator of inhibiting myocardial fibrosis, and hypertrophy, and promoting vascular repairment. Moreover, there exists a close association between cardiovascular risk factors such as hyperlipidemia, obesity, and diabetes mellitus with CVD. We also explore the mechanisms through which Chinese botanical drugs impact the intestinal mucosal barrier and regulate glucose and lipid metabolism. Consequently, these findings present novel insights and methodologies for treating CVD.

Citing Articles

Unraveling the gut: the pivotal role of intestinal mechanisms in Kawasaki disease pathogenesis.

Tao E, Lang D Front Immunol. 2024; 15():1496293.

PMID: 39664384 PMC: 11633670. DOI: 10.3389/fimmu.2024.1496293.


Sex Differences in Cardiovascular Diseases: Exploring the Role of Microbiota and Immunity.

Franza L, Caldarelli M, Villani E, Cianci R Biomedicines. 2024; 12(8).

PMID: 39200110 PMC: 11352091. DOI: 10.3390/biomedicines12081645.

References
1.
Baur J, Sinclair D . Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006; 5(6):493-506. DOI: 10.1038/nrd2060. View

2.
Zhang X, Chen J, Yi K, Peng L, Xie J, Gou X . Phlorizin ameliorates obesity-associated endotoxemia and insulin resistance in high-fat diet-fed mice by targeting the gut microbiota and intestinal barrier integrity. Gut Microbes. 2020; 12(1):1-18. PMC: 7714487. DOI: 10.1080/19490976.2020.1842990. View

3.
Wang Z, Zhang S, Han L, Chai S . Effects of xuesetong soft capsules on angiogenesis and VEGF mRNA expression in ischemic myocardium in rats with myocardial infarction. J Tradit Chin Med. 2012; 32(1):71-4. DOI: 10.1016/s0254-6272(12)60035-1. View

4.
Luo Z, Li H, Xiao Z, Shao S, Zhao T, Zhao Y . Taohong Siwu Decoction Exerts a Beneficial Effect on Cardiac Function by Possibly Improving the Microenvironment and Decreasing Mitochondrial Fission after Myocardial Infarction. Cardiol Res Pract. 2019; 2019:5198278. PMC: 6925791. DOI: 10.1155/2019/5198278. View

5.
Xu X, Li D, Gao H, Gao Y, Zhang L, Du Y . Protective effect of the traditional Chinese medicine xuesaitong on intestinal ischemia-reperfusion injury in rats. Int J Clin Exp Med. 2015; 8(2):1768-79. PMC: 4402752. View